President and CEO
Mr. Ferrara was most recently Founder, President and CEO of NeuroVia, Inc., a clinical stage orphan CNS disease company, where he raised a Series A financing, built an efficient team and established the clinical and regulatory strategy to lead the company into an efficacy study. Previously, he was at the Novartis Venture Fund (NVF), where he founded NeuroVia in 2013 amongst his other activities as an operating partner. He joined NVF from portfolio company Sorbent Therapeutics where he was consulting Chief Business Officer, raising $58M in financing and leading the refocusing of the company’s lead program. Prior roles include General Partner and Managing Director at Burrill & Company, after beginning his venture capital and business development career at GeneChem Management. In addition to his investing responsibilities at GeneChem, he was part of the business development team at BiocChem Pharma and held operating positions in portfolio companies, including CEO of Targanta Therapeutics. He received his MBA and MSc from McGill University.
Paolo Baroldi, MD
Chief Medical Officer
Dr. Baroldi most recently was EVP and Chief Medical Officer at Vanda Pharmaceuticals, where he led the team that successfully developed two NMEs for schizophrenia and a rare CNS orphan condition, called Non-24 Sleep-Wake Disorder. Previously, he was at Supernus, where he developed and registered in record time two new CR forms of antiepileptic drugs. Prior roles include VP for R&D at Chiesi Pharmaceuticals, and Global Head of Clinical Pharmacology at Novartis, where, with his large group of scientists, contributed to the international registration of more than ten NMEs, including new immunosuppressants and the breakthrough drug imatinib for CML. He has extensively worked on immunology related pathologies, like asthma and atopic dermatitis. He received his MD and PhD at University of Milan.
Richard Newman, PHD, DABT
Head of Regulatory Affairs
Dr. Newman has spent over 40 years in Regulatory Affairs, Pre-clinical, Clinical and Product Development. He established RnD Services, LLC in 2003 to provide regulatory, clinical and strategic development support providing consultancy to companies from Start-up through well-established companies with marketed products. Dr. Newman was Vice President of Research and Development, Regulatory Affairs and Clinical Affairs for Baxter Healthcare’s Renal Division from 1992 to 2002. Leading a team of over 300 scientists in the United States, Japan and Europe they developed a variety of products for patients on dialysis. Prior to joining Baxter, Dr. Newman spent eight years in Regulatory Affairs and Clinical Affairs with Searle Pharmaceuticals. While at Searle he directed product registration activities for a wide range of therapeutic products. For seven years prior to Searle, Dr. Newman was with Procter & Gamble working in their Professional and Regulatory Services group. Dr. Newman received his PhD from Texas A&M University and a BSc from Colorado State University. He has been a Diplomate of the American Board of Toxicology since 1981 and maintains certification.
Head of Finance
Benson Fong is responsible for Medeor Financial Operations and supports other operating activities. He has over 25 years of experience in financial and business development activities in drug development companies, including seeing CoTherix and Matrix Pharmaceuticals through their IPOs. He was SVP Corporate Development at CoTherix at the time of their acquisition by Actelion and was responsible for in-licensing Ventavis®. He has commercial banking experience in venture debt lending at Imperial Bank/Comerica and as a Division Controller in Express Banking at Wells Fargo Bank. Prior to entering banking and the healthcare industry, he was a tax accountant at Arthur Young & Co. He received his BS in Biology from the University of Oregon.
Suzanne Crowley, MS-CROM
Vice President, Clinical Operations
Suzanne (Sue) Crowley joined the Company in March 2019, and is responsible for all Medeor Clinical Operations. Previously she was at Swedish Orphan Biovitrum AB, North America between 2011 and 2019, where she served in several positions of increasing responsibility including Associate Director of Strategy and Director of Medical Affairs Operations. She also served as the president of her own consulting company between 2010 and 2014. She previously worked at Genzyme Transplant and 0ncology between 2003 and 2010, where she was the Director of External Research/Director of Global Pre-clinical ISS Program Transplant/Oncology. Before joining Genzyme, she was a Medical Science Liaison for SangStat, between 1999 and 2003.
Ms. Crowley is a nurse practitioner and received her BSN from Syracuse University and her MS-CROM from Drexel University, College of Medicine.